Results 181 to 190 of about 491,575 (216)

Selection of Chemotherapy in Hyperthermic Intraperitoneal Chemotherapy

2017
The peritoneum consists of a layer of mesothelial cells covering all abdominal organs and the abdominopelvic wall. Peritoneal metastases are formed after exfoliation of free tumor cells from a primary tumor invading the peritoneum. Consequently, most peritoneal metastases originate from abdominal organs such as the colon, rectum, stomach, or ovaria ...
H. J. Braam, F. J. H. Hoogwater
openaire   +1 more source

Scrotal Ulcer After Intraperitoneal Hyperthermic Chemotherapy

Urology, 2007
Tumor cytoreduction combined with intraperitoneal hyperthermic chemotherapy has been shown to be an effective method to delay the progression of peritoneal carcinomatosis. We describe 2 cases of painful scrotal ulcer after tumor debulking and intraperitoneal infusion of mitomycin-C for treatment of metastatic abdominal malignancies.
Ardavan, Akhavan, Ming, Yin, Ronald, Benoit   +2 more
openaire   +2 more sources

Intraoperative fluid restriction in hyperthermic intraperitoneal chemotherapy

Journal of Surgical Research, 2018
Multiple studies highlight the importance of liberal fluid administration in cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC). Over-resuscitation can delay recovery and wound healing. We report an intraoperative protocol that restricts fluid administration and minimizes morbidity.Retrospective analysis of 35 patients ...
Tariq Almerey, Emmanuel M. Gabriel, Klaus D. Torp, Sanjay P. Bagaria   +3 more
openaire   +2 more sources

Intraperitoneal and Hyperthermic Intraperitoneal Chemotherapy for the Treatment of Ovarian Cancer

Current Treatment Options in Oncology
In our clinical practice, we have shifted away from the use of adjuvant normothermic intraperitoneal (IP) chemotherapy, particularly following the publication of GOG 252. Our decision is rooted in the accumulating evidence indicating a lack of demonstrable superiority, alongside the recognized toxicities and logistical challenges associated with its ...
Joyce Y, Wang, Maya, Gross, Renata R, Urban, Soledad, Jorge   +3 more
openaire   +2 more sources

Hyperthermic Intraoperative Intraperitoneal Chemotherapy Safety Considerations

AORN Journal, 1996
ABSTRACTPerioperative staff members encounter many occupational exposure hazards in the workplace. Cytotoxic agent exposure is a relatively new hazard that perioperative staff members are experiencing as more surgeons use hyperthermic intraoperative intraperitoneal chemotherapy (HIIC) to treat patients with abdominopelvic cavity malignancies. Routes of
S K, White, A D, Stephens, P H, Sugarbaker   +2 more
openaire   +2 more sources

Adjuvant hyperthermic intraperitoneal chemotherapy for adenocarcinoma of the pancreas

1996
Each year in the United States, approximately 28,000 people develop cancer of the pancreas, resulting in an incidence of 9 cases per 100,000 population [1,2]. Although the incidence of cancers at several other sites is higher, pancreatic carcinoma is the fourth leading cause of cancer death behind malignancies of the lung, prostate, and colorectum in ...
S E, Ettinghausen, A M, Averbach
openaire   +2 more sources

Hyperthermic Intraperitoneal Chemotherapy: An Overview #412

Journal of Palliative Medicine, 2021
Ryan, Morgan, Sandy, Tun, Oliver S, Eng
openaire   +2 more sources

Ventricular tachycardia during hyperthermic intraperitoneal chemotherapy

Anaesthesia, 2009
Summary Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (HIPEC) is used for selected gastrointestinal carcinomas. We report a case of ventricular tachycardia during HIPEC with cisplatin that persisted as long as the chemotherapy solution remained in the intra‐abdominal cavity.
C A, Thix, I, Königsrainer, R, Kind, P, Wied, T H, Schroeder   +4 more
openaire   +2 more sources

The approval process for hyperthermic intraoperative intraperitoneal chemotherapy

European Journal of Surgical Oncology (EJSO), 2006
To clarify the requirements for Food and Drug Administration approval in the United States for hyperthermic intraoperative intraperitoneal chemotherapy administration. Also, to review the status of the approval process in Europe.The obstacles to be overcome for approval by the Food and Drug Administration for a new drug approval and for a new device ...
P H, Sugarbaker, L, Clarke
openaire   +2 more sources

Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy

BJA Education, 2021
S, Durnford, L, Boss, J, Bell
openaire   +2 more sources